2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Japan stands at a crossroads where U.S. policy pressures, rising private equity interest, and landmark deals are testing its willingness to reform. The outcome could reshape the nation’s role in global pharma and investment.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.
